Results 191 to 200 of about 60,794 (276)

Malignancy in Pediatric Hyperfunctioning Thyroid Nodules: A Case Report and Literature Review

open access: yesClinical Endocrinology, Volume 105, Issue 4, Page 474-485, October 2026.
ABSTRACT Background Thyroid nodules are rare in children but carry a markedly higher risk of malignancy compared to adults (20%–26% vs. 5%). Hyperfunctioning thyroid nodules are exceptionally uncommon in the pediatric population and are typically benign.
Cristina Clausi   +12 more
wiley   +1 more source

Association of resection type, nodal evaluation, and survival in early-stage lung squamous cell carcinoma. [PDF]

open access: yesJ Thorac Dis
Alexander E   +7 more
europepmc   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1510-1520, 15 September 2026.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier   +19 more
wiley   +1 more source

Primary pulmonary leiomyosarcoma in a patient with disseminated pulmonary tuberculosis and constrictive pericarditis. [PDF]

open access: yesRespir Med Case Rep
Van Der Westhuizen S   +5 more
europepmc   +1 more source

Extended sleeve lobectomy after neoadjuvant chemo-immunotherapy: postoperative outcomes differ by surgical side. [PDF]

open access: yesTransl Lung Cancer Res
Wen J   +14 more
europepmc   +1 more source

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers, Part II: Follow-up Surveillance after Initial Treatment 2026. [PDF]

open access: yesEndocrinol Metab (Seoul)
Lee EK   +32 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy